Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vudalimab + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Vudalimab + carboplatin + pemetrexed** is a combination regimen studied as first-line therapy for advanced nonsquamous non-small cell lung cancer (NSCLC). Vudalimab (XmAb20717) is a bispecific monoclonal antibody targeting PD-1 and CTLA-4, designed to block two immunosuppressive pathways simultaneously, thereby enhancing T-cell mediated anti-tumor responses. Carboplatin and pemetrexed are standard chemotherapy agents for NSCLC; carboplatin is a platinum-based DNA-damaging agent, while pemetrexed is an anti-folate that disrupts DNA synthesis. This combination aims to unite checkpoint blockade-induced immune activation with direct cytotoxic effects from chemotherapy[1][4][5].
- Other names
- vudalimab + carboplatin + pemetrexed
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNACTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on vudalimab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vudalimab + carboplatin + pemetrexed.